Lutetium-177 Beats Everolimus in Phase 3 Neuroendocrine Tumor Trial
The COMPETE trial shows radioligand therapy extends progression-free survival by nearly 10 months vs. standard targeted therapy in GEP NETs.
Summary
A major phase 3 trial called COMPETE compared two approved treatments for advanced gastroenteropancreatic neuroendocrine tumors: a radioligand therapy called lutetium-177 edotreotide versus the mTOR inhibitor everolimus. Across 309 patients from 14 countries, those receiving the radioligand therapy lived significantly longer without disease progression — nearly 24 months compared to 14 months for everolimus. The radioligand also produced fewer severe side effects: only 18% of patients experienced grade 3–4 adverse events versus 40% on everolimus. No treatment-related deaths occurred in either group. These results support moving radioligand therapy earlier in the treatment sequence for patients with somatostatin receptor-positive GEP NETs, potentially reshaping clinical practice guidelines for this increasingly diagnosed cancer type.
Detailed Summary
Gastroenteropancreatic neuroendocrine tumors (GEP NETs) are a heterogeneous group of cancers arising in the digestive tract and pancreas. While once considered rare, their incidence has risen steadily, and metastatic disease remains difficult to manage. Two broad treatment classes — peptide receptor radionuclide therapy (PRRT) and mTOR-targeted therapy — are both approved, but head-to-head comparative evidence has been largely absent. The COMPETE trial was designed to address this directly.
Researchers enrolled 324 patients across 49 specialist centers in 14 countries, randomizing 309 of them 2:1 to receive either intravenous [177Lu]Lu-edotreotide every three months (up to four cycles) or oral everolimus daily for up to 30 months. Patients had grade 1–2, unresectable or metastatic GEP NETs that were somatostatin receptor-positive. The trial included both treatment-naive and previously treated patients, with stratification by tumor origin and prior therapy.
The primary endpoint — progression-free survival assessed by blinded independent central review — strongly favored the radioligand arm. Median progression-free survival was 23.9 months with [177Lu]Lu-edotreotide versus 14.1 months with everolimus, a statistically significant difference (hazard ratio 0.67; p=0.022). Beyond efficacy, the safety profile also favored the radioligand: grade 3–4 adverse events occurred in 18% versus 40% of patients, and no treatment-related deaths occurred in either group.
These findings carry meaningful clinical implications. The combination of superior tumor control and a more favorable tolerability profile suggests [177Lu]Lu-edotreotide may be preferable not just as a later-line rescue option, but as an earlier intervention in the treatment algorithm for eligible patients.
Several caveats apply. The open-label design introduces potential bias. Follow-up was somewhat asymmetric between arms. The trial was funded by ITM, the manufacturer of [177Lu]Lu-edotreotide, and multiple authors reported industry relationships. Additionally, this summary is based on the abstract only, as the full text was not available.
Key Findings
- Median progression-free survival: 23.9 months with lutetium-177 edotreotide vs. 14.1 months with everolimus.
- Radioligand therapy reduced progression or death risk by 33% (HR 0.67, p=0.022) versus everolimus.
- Severe grade 3–4 adverse events were less than half as common with radioligand therapy (18% vs. 40%).
- No treatment-related deaths occurred in either arm across 309 randomized patients.
- Results support use of lutetium-177 edotreotide in earlier lines of therapy for advanced GEP NETs.
Methodology
COMPETE was a phase 3, open-label, superiority trial randomizing 309 patients 2:1 to [177Lu]Lu-edotreotide or everolimus across 49 centers in 14 countries. Primary endpoint was progression-free survival at 30 months via blinded independent central review. Randomization was stratified by primary tumor origin and prior therapy history.
Study Limitations
The open-label design may introduce performance or assessment bias, though the primary endpoint used blinded central review. The trial was industry-funded by ITM, the manufacturer of the experimental agent, and most investigators reported financial relationships with industry. This summary is based on the abstract only, as the full paper was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: